  The term bacteriophage means killer or eater of bacteria. They were initially
discovered by F.W. Twort and later on, Felix d'Herelle unveiled them to the
world in 1910. Phage therapy has arisen as a favorable option to conventional
antibiotics by reducing the multinational problem of increasing antibacterial
resistance. These virulent viruses particularly prey on and contaminate
bacterial strains and aid in fighting bacterial diseases. Researchers are
performing various clinical trials on the bacteriophage to tackle pathogenic
bacterial infections, varying from typical illnesses to highly invulnerable
biofilms that cannot be treated with antibiotics. The primary experiments
demonstrated that phage therapy has fewer consequences than traditional
antimicrobial drugs. It is safer to use and show results within a few days.
Although phage therapy has a wide range of promising results, but it also
encounters diverse obstacles. One is that they are host-specific and can merely
be used for personalized therapy. As thousands of bacteria can cause disease,
clinicians have to construct a library of phage viruses. For successful
treatment, an analysis of versatility, stability, and immune interference
related to bacteriophage is necessary. Phage therapy is an excellent substitute
for antibiotics as it illustrates a living base for the treatment of infections
and it is climate-friendly. It only targets the pathogenic cells and has less
influence on the normal microbiota. Regardless of the challenges and problems,
phage therapy is approved as a beneficial approach to combating contagious
infections.
